Table 5.

Key indications for molecular imaging in PCC/PGL

▪ Diagnosis and localisation of adrenal-and extra-adrenal PCC/PGL in patients with elevated catecholamine levels.

▪ Staging of patients prior to surgical resection to exclude metastatic or additional primary sites of disease.

▪ Selection of patients for radionuclide therapy with 177Lu/90Y radiolabelled DOTATATE or 131I-MIBG therapy.

▪ Response assessment following chemotherapy or targeted therapies.

▪ Surveillance of patients with inherited mutations such as SDHxor VHL